跳至主要内容
临床试验/NCT03649646
NCT03649646已完成不适用

A Multi-center, Open, Longitudinal, Observational Study to Assess the Treatment Trend and the Proportion of Target BP Attainment in Patients Whose Antihypertensive Regimens Are Changed to ARB-based Therapy

Boryung Pharmaceutical Co., Ltd1 个研究点 分布在 1 个国家目标入组 4,542 人开始时间: 2018年7月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
4,542
试验地点
1
主要终点
Percentage of Patients With Controlled Blood Pressure (<140/90 mmHg)

研究概览

简要总结

The recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in hypertension treatment. However, studies in Koreans must be preceded before applying such new overseas guidelines; thus, this study has been designed to establish clinical materials reflecting treatment setting in Korea. In this study, patients with uncontrolled hypertension whose antihypertensive regimens are changed to ARB-based therapy (ARB monotherapy or ARB-containing combination therapy) will be followed to assess the treatment trend, treatment effect, and risk of cardiovascular disease.

详细描述

This study will be performed in patients with blood pressure (BP) uncontrolled by existing antihypertensive drugs (including ARB) among hypertensive patients visiting outpatient clinic of medical institutions in Korea. The study enrollment number will be assigned to the subjects who provide a written consent to the use of personal information and meet the inclusion/exclusion criteria. Follow-up will be conducted for 12 weeks in total and prespecified study related data will be collected in the case report form.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provided written consent to the use of personal information after receiving the explanation of the objective, methodology, etc. of this clinical study
  • Male or female adults ≥ 19 years who are diagnosed with essential hypertension
  • Receiving outpatient treatment at the time of study enrollment
  • Patients with hypertension uncontrolled by existing antihypertensive drugs (including ARB) whose antihypertensive regimens decided and scheduled to be changed to ARB monotherapy or ARB-containing combination therapy (the result of the arm with a higher mean BP [systolic BP preferred] when measured twice with at least a 2-minute interval in both arms at the medical office on the study enrollment date, will become the reference)
  • Definition of uncontrolled hypertension: Target BP (SBP <140 mmHg and DBP <90 mmHg) not achieved even after the treatment using the existing antihypertensive drugs for 4 weeks or longer

排除标准

  • Patients who were hospitalized or are scheduled to be hospitalized 4 weeks before or after the study enrollment date
  • Patients with suspected or confirmed secondary hypertension
  • Pregnant or breast-feeding women
  • Patients who received investigational product within 12 weeks or are scheduled to participate in another clinical study while participating in this study
  • Patients who are determined inappropriate for participating in the study by investigators for other reasons

结局指标

主要结局

Percentage of Patients With Controlled Blood Pressure (<140/90 mmHg)

时间窗: Week 12 after the treatment regimen change

Percentage of patients who attain the target blood pressure (BP) (\<140(SBP)/90(DBP) mmHg) at Week 12 after the treatment regimen change

次要结局

  • Percentage of Patients With Controlled BP According to 2018 KSH Guideline(Week 12 after the treatment regimen change)
  • Percentage of Patients With Controlled BP According to 2017 ACC/AHA Guideline(Week 12 after the treatment regimen change)
  • Prcentage of Patients With Controlled BP According to Investigator's Target BP(Week 12 after the treatment regimen change)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验